论文部分内容阅读
目的 :观察 CHOP方案对儿童不同细胞来源中高度非何杰金恶性淋巴瘤(NHL)的疗效及不良反应。方法 :CHOP方案 (CTX75 0 mg/m2 静注 d1 ,VCR1 .4m g/m2 静注d1 、8,ADM40 m g/m2静注 d1 ,PDN1 0 0 mg/m2口服 d1～ 5,2 1 d重复 ,共用 2周期 )治疗病理学证实的儿童中高度非何杰金恶性淋巴瘤 2 5例 ,观察其疗效和不良反应。结果 :2 5例病人完全缓解率 40 % ,总有效率 92 % ,T细胞型总有效率 75 % ,B细胞型总有效率 1 0 0 % ,初治病人有效率 1 0 0 % ,复治病人有效率 71 % ,主要不良反应为骨髓抑制 , ～ 度白细胞减少占 2 4% ,血小板减少程度较轻。结论 :CHOP化疗方案是治疗儿童中高度非何杰金恶性淋巴瘤安全有效的方案 ,对 B细胞来源儿童 NHL疗效明显优于 T细胞来源者
Objective: To observe the efficacy and side effects of CHOP regimen in highly non-Hodgkin’s lymphoma (NHL) in children with different cell sources. Methods: CHOP regimen (CTX75 0 mg / m2 intravenous d1, VCR1 .4 m g / m2 intravenous d1, 8, ADM40 mg / m2 intravenous d1 PDN1 0 mg / m2 orally d1 5,2 1 d repeated, Shared 2 cycles) 25 cases of highly non-Hodgkin’s malignant lymphoma confirmed by pathology in children, observed the efficacy and adverse reactions. Results: The complete remission rate was 40% in 25 patients, the total effective rate was 92%, the total effective rate of T cell type was 75%, the total effective rate of B cell type was 100%, the effective rate of newly diagnosed patients was 100% Treatment of patients with effective rate of 71%, the main adverse reactions of bone marrow suppression, ~ 20% of leukopenia, thrombocytopenia less. Conclusion: CHOP chemotherapy is safe and effective in the treatment of children with non-Hodgkin’s lymphoma, and the efficacy of CHOP is superior to that of T cells in children with B cell